- Home
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Team
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- IPCA LABORATORIES LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
IPCA Labs Quarterly Results 
(IPLB)
Here are the latest quarterly results of IPCA Labs. For more details, see the IPCA Labs financial fact sheet and IPCA Labs share price and chart. For a sector overview, read our pharmaceuticals sector report.
IPCA Labs Quarterly Results
| No. of Mths Qtr. Ending |
3
Jun-15 |
3
Sep-15 |
3
Dec-15 |
3
Mar-16 |
3
Jun-16 |
3
Sep-16 |
3
Dec-16 |
3
Mar-17* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 7,580 | 7,492 | 6,841 | 6,246 | 8,422 | 8,851 | 7,507 | 6,658 | |
| Other income | Rs m | 41 | 53 | 50 | 87 | 49 | 62 | 59 | 52 | |
| Turnover | Rs m | 7,621 | 7,545 | 6,891 | 6,333 | 8,470 | 8,913 | 7,567 | 6,710 | |
| Expenses | Rs m | 6,874 | 6,839 | 5,957 | 5,639 | 7,218 | 7,492 | 6,443 | 5,981 | |
| Gross profit | Rs m | 822 | 892 | 884 | 526 | 1,204 | 1,358 | 1,065 | 677 | |
| Depreciation | Rs m | 421 | 437 | 448 | 392 | 422 | 429 | 432 | 428 | |
| Interest | Rs m | 55 | 70 | 91 | 0 | 65 | 68 | 57 | 44 | |
| Profit before tax | Rs m | 388 | 438 | 394 | 221 | 766 | 924 | 636 | 257 | |
| Tax | Rs m | 82 | 82 | 162 | 156 | 290 | 374 | 222 | -187 | |
| Profit after tax | Rs m | 305 | 356 | 232 | 65 | 476 | 550 | 414 | 444 | |
| Gross profit margin | % | 10.8 | 11.9 | 12.9 | 8.4 | 14.3 | 15.3 | 14.2 | 10.2 | |
| Effective tax rate | % | 21.3 | 18.8 | 41.2 | 70.7 | 37.9 | 40.5 | 34.9 | -72.7 | |
| Net profit margin | % | 4.0 | 4.7 | 3.4 | 1.0 | 5.6 | 6.2 | 5.5 | 6.7 | |
| Diluted EPS | Rs | 2.4 | 2.8 | 1.8 | 0.5 | 3.8 | 4.4 | 3.3 | 3.5 | |
| Diluted EPS (TTM) | Rs | 11.0 | 8.2 | 5.9 | 7.6 | 8.9 | 10.5 | 11.9 | 14.9 | |
 Subscriber Feature |
View | View | ||||||||
Interim results exclude extraordinary / exceptional items
More Pharmaceuticals Company Quarterly Results: ALEMBIC PHARMA WYETH LTD SANOFI INDIA BIOCON LTD VENUS REMEDIES
Compare IPCA LABS With: ALEMBIC PHARMA WYETH LTD SANOFI INDIA BIOCON LTD VENUS REMEDIES
Compare IPCA LABS With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Closes above 100 Points; IT & Realty Stocks Rally(Closing)
Indian share markets gathered some momentum in the afternoon session to finish above the dotted line amid firm global markets.
Views on news
Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)
Sep 22, 2017Muted growth in CRAMS segment continues to impact topline.
Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)
Aug 14, 2017A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)
Aug 14, 2017GST impact coupled with price erosion in US leads to lower profits for the quarter.
Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)
Aug 8, 2017Profits plunge due to higher raw material costs.
Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)
Jun 23, 2017Net Profit lower due to exceptional items in the previous year.
More Views on NewsMost Popular
Timeless Stocks on the Electric Car Assembly Line(The 5 Minute Wrapup)
Oct 10, 2017Are they on their way to create Coca Cola-like wealth?
Why Merger of Public Sector Banks Continues to Be a Bad Idea(Vivek Kaul's Diary)
Oct 10, 2017There is enough research evidence that suggests that most mergers don't work.
Electric Vehicles: The Final Piece of the Puzzle(Smart Contrarian)
Oct 16, 2017Just as there would be gainers from an electric vehicles boom, who possibly could be the biggest losers.
Mutual Funds Re-categorised... But What About Stocks?(Daily Profit Hunter)
Oct 11, 2017The market regulator can solve systemic issues but you must tackle the behavioral biases on your own.
Companies Are Wary of Borrowing(Chart Of The Day)
Oct 17, 2017How to profit from behavioral biases afflicting the industry.
More|
| |
IPCA LABS SHARE PRICE
Oct 23, 2017 (Close)
TRACK IPCA LABS
- Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON IPCA LABS
IPCA LABS - ALEMBIC LTD COMPARISON
COMPARE IPCA LABS WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
